METFORMIN AND EMPAGLIFLOZIN clinical trials

Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF): the INITIATE-HFrEF randomized open-label trial

This study is looking at new ways to treat heart failure where the heart struggles to pump blood effectively. It compares different combinations of existing medicines to see which approach works best and is safest for patients over a six-month period.